Last reviewed · How we verify
Mirvetuximab soravtansine plus Bevacizumab
Mirvetuximab soravtansine plus Bevacizumab is a Antibody-drug conjugate (mirvetuximab soravtansine) + monoclonal antibody (bevacizumab) Small molecule drug developed by AbbVie. It is currently in Phase 3 development for Platinum-resistant ovarian cancer (folate receptor alpha positive), Recurrent ovarian cancer. Also known as: MIRV.
Mirvetuximab soravtansine targets folate receptor alpha on cancer cells to deliver a cytotoxic payload, while bevacizumab blocks VEGF to inhibit tumor angiogenesis.
Mirvetuximab soravtansine targets folate receptor alpha on cancer cells to deliver a cytotoxic payload, while bevacizumab blocks VEGF to inhibit tumor angiogenesis. Used for Platinum-resistant ovarian cancer (folate receptor alpha positive), Recurrent ovarian cancer.
At a glance
| Generic name | Mirvetuximab soravtansine plus Bevacizumab |
|---|---|
| Also known as | MIRV |
| Sponsor | AbbVie |
| Drug class | Antibody-drug conjugate (mirvetuximab soravtansine) + monoclonal antibody (bevacizumab) |
| Target | Folate receptor alpha (FRA) and VEGF |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) that binds folate receptor alpha (FRA), which is highly expressed on ovarian and other cancers, and delivers a microtubule-disrupting agent (DM4) intracellularly. Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF) that prevents tumor neovascularization. The combination leverages dual mechanisms: targeted cytotoxicity via FRA and anti-angiogenic activity via VEGF inhibition.
Approved indications
- Platinum-resistant ovarian cancer (folate receptor alpha positive)
- Recurrent ovarian cancer
Common side effects
- Neuropathy (peripheral)
- Anemia
- Thrombocytopenia
- Hypertension
- Fatigue
- Nausea
Key clinical trials
- A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (PHASE3)
- A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. (PHASE2)
- Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer (PHASE3)
- A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer (PHASE2)
- Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer (PHASE1, PHASE2)
- Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mirvetuximab soravtansine plus Bevacizumab CI brief — competitive landscape report
- Mirvetuximab soravtansine plus Bevacizumab updates RSS · CI watch RSS
- AbbVie portfolio CI
Frequently asked questions about Mirvetuximab soravtansine plus Bevacizumab
What is Mirvetuximab soravtansine plus Bevacizumab?
How does Mirvetuximab soravtansine plus Bevacizumab work?
What is Mirvetuximab soravtansine plus Bevacizumab used for?
Who makes Mirvetuximab soravtansine plus Bevacizumab?
Is Mirvetuximab soravtansine plus Bevacizumab also known as anything else?
What drug class is Mirvetuximab soravtansine plus Bevacizumab in?
What development phase is Mirvetuximab soravtansine plus Bevacizumab in?
What are the side effects of Mirvetuximab soravtansine plus Bevacizumab?
What does Mirvetuximab soravtansine plus Bevacizumab target?
Related
- Drug class: All Antibody-drug conjugate (mirvetuximab soravtansine) + monoclonal antibody (bevacizumab) drugs
- Target: All drugs targeting Folate receptor alpha (FRA) and VEGF
- Manufacturer: AbbVie — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Platinum-resistant ovarian cancer (folate receptor alpha positive)
- Indication: Drugs for Recurrent ovarian cancer
- Also known as: MIRV
- Compare: Mirvetuximab soravtansine plus Bevacizumab vs similar drugs
- Pricing: Mirvetuximab soravtansine plus Bevacizumab cost, discount & access